Searchable abstracts of presentations at key conferences in endocrinology

ea0035p476 | Diabetes therapy | ECE2014

Could favorable effects of liraglutide on steato-hepatitis be independent of weight loss in type 2 diabetes? A case report

Garcia Cyril , Bordier Lyse , Dupuy Olivier , Mayaudon Herve

Introduction: Some data suggest a favorable effect of glucagon-like peptide 1 (GLP1) on steato-hepatitis (SH) in type 2 diabetes. We report here a case of improvement of SH in a patient treated by liraglutide.Patients and methods: A 31-year-old woman presented type 2 diabetes. Her weight was 80 kg for 1.58 m (BMI=32 kg/m2). A treatment by liraglutide was initiated at 1.2 mg/day, percutaneously. A regular follow-up was performed with the record...

ea0035p526 | Endocrine tumours and neoplasia | ECE2014

The use of demeclocyclin in the syndrome of paraneoplastic inappropriated secretion of anti-diuretic hormone: about one observation

Garcia Cyril , Poncin Thibault , Legarlantezec Patrick , Bordier Lyse , Mayaudon Herve , Dupuy Olivier , Cremades Serge

Introduction: Hyponatraemia constitutes the most common hydro-electrolytic abnormality and the determination of its cause is important for patient’s treatment, which can include the use of a pharmacological agent.Observation: A 78-year-old woman suffering from a lung adenocarcinoma presents a chronic hyponatraemia ranging from 114 to 123 mmol/l, which cannot be corrected by fluid limitation alone. Clinical and biological assessment leads to diagnose...

ea0037gp.30.01 | Endocrine tumours and neoplasia – General | ECE2015

Temozolomide treatment for pituitary aggressive tumours and pituitary carcinomas: initial results and long-term follow-up of a cohort of 32 cases

Lasolle Helene , Castinetti Frederic , Cortet Christine , Cloix Lucie , Batisse-Lignier Marie , Bonnet Fabrice , Bourcigaux Nathalie , Chabre Olivier , Chanson Philippe , Delemer Brigitte , Lebrun-Frenay Christine , Garcia Cyril , Reznik Yves , Schillo Franck , Taillandier Luc , Maiter Dominique , Sadoul Jean-Louis , Caron Philipe , Raverot Gerald

Context: Successful used of temozolomide (TMZ) treatment has been described in 40–50% of aggressive pituitary tumour (PT) or rare pituitary carcinoma. These results are based on 50 case-reports and small series, data on long-term follow-up being rare.Objectives: To describe initial results and long-term follow-up of a large French cohort of patients presenting PT treated with temozolomide.Design: Members of the French Society ...